CN109963835A - 一种新毒素及其中间体的制备方法 - Google Patents

一种新毒素及其中间体的制备方法 Download PDF

Info

Publication number
CN109963835A
CN109963835A CN201880004457.6A CN201880004457A CN109963835A CN 109963835 A CN109963835 A CN 109963835A CN 201880004457 A CN201880004457 A CN 201880004457A CN 109963835 A CN109963835 A CN 109963835A
Authority
CN
China
Prior art keywords
formula
base
antibody
compound shown
benzotriazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004457.6A
Other languages
English (en)
Other versions
CN109963835B (zh
Inventor
许建烟
章瑛
屈博磊
蒋贵阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109963835A publication Critical patent/CN109963835A/zh
Application granted granted Critical
Publication of CN109963835B publication Critical patent/CN109963835B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

一种新毒素及其中间体的制备方法，具体包含通式(III)化合物及其制备方法，以及通式(III)化合物经过一系列的上保护基、脱保护基和缩合反应得到通式(I)化合物的制备方法。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN201880004457.6A 2017-09-04 2018-09-03 一种新毒素及其中间体的制备方法 Active CN109963835B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017107853969 2017-09-04
CN201710785396 2017-09-04
PCT/CN2018/103781 WO2019042447A1 (zh) 2017-09-04 2018-09-03 一种新毒素及其中间体的制备方法

Publications (2)

Publication Number Publication Date
CN109963835A true CN109963835A (zh) 2019-07-02
CN109963835B CN109963835B (zh) 2022-10-21

Family

ID=65526239

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004457.6A Active CN109963835B (zh) 2017-09-04 2018-09-03 一种新毒素及其中间体的制备方法

Country Status (3)

Country Link
CN (1) CN109963835B (zh)
TW (1) TW201912626A (zh)
WO (1) WO2019042447A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109912684A (zh) * 2019-03-08 2019-06-21 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体
CN113813399A (zh) * 2021-04-19 2021-12-21 联宁（苏州）生物制药有限公司 喜树碱类化合物、其抗体药物偶联物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254342A (zh) * 2011-12-14 2014-12-31 西雅图基因公司 新抗体药物缀合物(adc)及其用途
WO2016127790A1 (zh) * 2015-02-15 2016-08-18 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
WO2017144015A1 (zh) * 2016-02-26 2017-08-31 江苏恒瑞医药股份有限公司 一种新毒素及其中间体的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018140275A2 (en) * 2017-01-26 2018-08-02 Seattle Genetics, Inc. Novel auristatin derivatives and related antibody-drug conjugates (adcs) and methods of preparation thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254342A (zh) * 2011-12-14 2014-12-31 西雅图基因公司 新抗体药物缀合物(adc)及其用途
WO2016127790A1 (zh) * 2015-02-15 2016-08-18 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
WO2017144015A1 (zh) * 2016-02-26 2017-08-31 江苏恒瑞医药股份有限公司 一种新毒素及其中间体的制备方法

Also Published As

Publication number Publication date
CN109963835B (zh) 2022-10-21
TW201912626A (zh) 2019-04-01
WO2019042447A1 (zh) 2019-03-07

Similar Documents

Publication Publication Date Title
KR100937915B1 (ko) 변형된 픽텟-스펭글러 반응 및 그것으로부터 제조된생성물
CN109843890B (zh) 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109963835A (zh) 一种新毒素及其中间体的制备方法
TWI732826B (zh) 一種新毒素及其中間體的製備方法
KR101191977B1 (ko) 2,5-다이케토피페라진 화합물의 제조방법
GB2056437A (en) Secoergoline derivatives
Yoshida et al. Synthesis of granulatimide positional analogues
SATO et al. Application of remote photocyclization with a pair system of phthalimide and methylthio groups. A photochemical synthesis of cyclic peptide models
Allevi et al. A simple and convenient transformation of l-lysine into pyridinoline and deoxypyridinoline, two collagen cross-links of biochemical interest
CN108997448B (zh) 一种吡喃糖环吡咯螺缩酮生物碱的全合成方法及应用
CN111606888B (zh) 吡咯类衍生物及其制备方法与应用
HARADA et al. New Route to 1, 3, 3a, 8a-Tetrahydro-2H-benzofuro [2, 3-b] pyrrol-2-ones from Methyl α-Hydroxy-4H-1, 2-benzoxazine-4-acetates Obtained by Ring Transformation of 4-Aryl-2-isoxazoline 2-Oxides
Fodor et al. Preparation and ring transformation of isomeric β-lactam derivatives of bicyclic 1, 3-thiazines
CN111808040B (zh) 多构型2-氧代噁唑烷-4-羧酸类化合物的合成方法
CA3110519A1 (en) Process for manufacturing pibrentasvir active drug substance
Kurbatov et al. Bicyclic ortho-aminocarbonitriles—New accessible synthons.
Coolen et al. Chiral basket‐shaped host compounds derived from diphenylglycoluril
CA3168355A1 (en) Macrocyclic indole derivatives as inhibitors of mcl-1
NO870374L (no) Fremgangsmaate til fremstilling av substituerte pyrrolidinoner.
WO2023230236A1 (en) Process for preparing jak inhibitors and intermediates thereof
CN116969976A (zh) 去泛素化酶抑制剂及其应用
CN116217478A (zh) 一种6-氨基-3-二氟甲基喹啉的合成方法
CN113861097A (zh) 一种多构型1-Boc-N-Fmoc色氨酸类化合物的合成方法
原田和穂 et al. Synthetic Reactions of Isoxazoline 2-oxides. Part XIV. New Route to 1, 3, 3a, 8a-Tetrahydro-2H-benzofuro (2, 3-b) pyrrol-2-ones from Methyl. ALPHA.-Hydroxy-4H-1, 2-benzoxazine-4-acetates Obtained by Ring Transformation of 4-Aryl-2-isoxazoline 2-Oxides.
HARADA et al. Transformation of 4-Aryl-2-isoxazoline 2-0xides”

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40009383

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant